Core Viewpoint - The article highlights the systematic policy support for innovative drugs in China, emphasizing the role of companies like Baiaosaitu in driving global innovation through their RenMice platform [1][12]. Group 1: Policy Support for Innovative Drugs - The National Healthcare Security Administration and the National Health Commission have jointly released measures to support the high-quality development of innovative drugs, focusing on real-world data, dynamic adjustment of medical insurance catalogs, and commercial health insurance [1]. - The policy aims to make innovative drugs more accessible and affordable through optimized payment systems and mechanisms [1]. Group 2: Baiaosaitu's RenMice Platform - Baiaosaitu has developed the RenMice platform, which includes various technologies such as RenMab, RenLite, RenNano, and RenTCR, covering all necessary tools for next-generation antibody drug development [3]. - The platform's originality lies in its ability to produce fully human antibodies directly from engineered mice, significantly reducing time and costs while avoiding immunogenic risks [3]. - The RenMice platform has secured patents in over ten countries, establishing a comprehensive international intellectual property layout, which enhances the marketability of its antibody products [4]. Group 3: Clinical Applications and Collaborations - Baiaosaitu has signed over 200 drug cooperation agreements, with more than 50 projects entering IND and clinical stages, showcasing the platform's practical value [6]. - Notable projects include NTB003, a second-generation fully human antibody targeting IGF-1R, and several dual-antibody ADC projects that have received IND approvals from regulatory bodies [6][7]. - The company acts not only as an antibody provider but also as a drug design partner, enhancing the efficiency and success rate of projects moving from early research to clinical trials [7]. Group 4: Expansion of Technology and Future Potential - Baiaosaitu is expanding its technology beyond traditional antibody platforms to include novel therapeutic areas such as nanobodies and TCR-based therapies, indicating a broader scope for drug discovery [9]. - The RenTCR-mimic platform opens new target spaces for antibody recognition of intracellular antigens, potentially addressing previously "undruggable" targets [9]. - The company's approach to solving complex system issues positions it as a comprehensive solution provider in drug discovery, moving beyond being merely a tool provider [9]. Group 5: Long-term Value and Market Position - Baiaosaitu exemplifies a "long-term compounding" success model in the Chinese innovative drug sector, focusing on platform stickiness, intellectual property strength, and international commercial viability [11][12]. - The company's ongoing efforts in antibody development and collaboration are shaping the future landscape of new drug ecosystems in China, raising the question of whether more global drugs will be "Made by China" [12].